# A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL

> **NCT01544348** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 295 (actual)

## Conditions studied

- Allergic Asthma
- Atopic Dermatitis
- Allergic Rhinitis
- Healthy Volunteers

## Interventions

- **OTHER:** Placebo
- **BIOLOGICAL:** Omalizumab
- **BIOLOGICAL:** MEDI4212 5 mg Subcutaneous
- **BIOLOGICAL:** MEDI4212 15 mg Subcutaneous
- **BIOLOGICAL:** MEDI4212 60 mg Subcutaneous
- **BIOLOGICAL:** MEDI4212 150 mg Subcutaneous
- **BIOLOGICAL:** MEDI4212 300 mg Subcutaneous
- **BIOLOGICAL:** MEDI4212 300 mg Intravenous

## Key facts

- **NCT ID:** NCT01544348
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 295 (ACTUAL)
- **Last updated:** 2014-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01544348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01544348, "A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01544348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*